Reporting from: – European Society for Medical Oncology Congress, October 29-November 10, 2004, Vienna – Journal of Clinical Oncology – New England Journal of Medicine – Lancet
Reporting from:
– European Society for Medical Oncology Congress, October 29-November 10, 2004, Vienna
– Journal of Clinical Oncology
– New England Journal of Medicine
– Lancet
In this edition:
The ESMO conference in Vienna heard news from Charles Butts that patients with advanced lung cancer have responded to a vaccine.
Diane Harper describes from her article the protection a vaccine has given against human papillomavirus types 16 and 18, raising hopes that widespread prevention of cervical cancer could be undertaken by immunization.
Daniel Haller told delegates at ESMO that his phase III study shows that the IROX combination of irinotecan plus oxaliplatin is superior to irinotecan monotherapy and does not add toxicity.
George Canellos reflects on the immune processes holding follicular lymphoma cells in check as revealed by a New England Journal of Medicine article looking at gene profiles and their prognostic implications for this variable disease.
…
Related Episodes
Charles E Geyer MD; ESMO 2025: Antibody Drug Conjugate T-DXd Brings Longer Cancer-Free Survival for Patients with HER2-Positive Early Breast Cancer and Residual Invasive Disease
Charles E Geyer MD, at ESMO 2025, discusses DESTINY-Breast05 results, revealing trastuzumab deruxtecan (T-DXd) significantly improves disease-free survival for HER2-positive early breast cancer patients with residual invasive disease after neoadjuvant therapy. T-DXd outperformed trastuzumab emtansin
Li Zhang MD; ESMO 2025: Patients with EGFR-mutated Lung Cancer Progressing After Tyrosine Kinase Therapy Live Longer with Sacituzumab Tirumotecan Therapy
Antibody Drug Conjugate Prolongs Life in NSCLC refractory to EGFR TKI Therapy
Xiuning Le MD PhD; ESMO 2025: Sevabertinib Success for Patients with HER2-Mutated Non-Small Cell Lung Cancer in SOHO-01 Study
A new anti cancer drug sevabertinib, that targets mutated HER2, has proved effective in the SOHO-01 study among patients wiith HER2 mutated non small cell lung cancer. It has now been reported in the